Synthesis process is carried out in about 35 minutes, and quality control tests were performed to ensure the good quality of product. The specific activity of (R)-[N-MethyJ-11C]PKI1195 was 25±10 GBq/l1mol, and radiochemical purity was better than 95%.
INTRODUCTION
Inflammation, in general, is a physiological response of the body to different types of tissue injury, causing a cascade of coordinated cellular and chemical reactions. The inflammatory process isolates the damaged tissue and promotes an immune response [1] . Likewise, neuroinflammation implicates a com plex orchestrated response to various stimuli in the central nervous system (CNS) aiming toward tissue preservation and restoration. Neuroinflammatory reactions involve a cellular response by activating cells of the monocyte lineage, whether resident or circulating. Microglia are the resident cells of the monocyte lineage in the CNS and their activation constitutes a main feature of neuroinflammation [2] . This activated stage of microglia, upregulates the expres sion of the 18 kDa trans locator protein (TSPO), which can be detected in vivo by positron emission tomography (PET) imag ing using selective TSPO radio ligands [3] . One of the fIrst PET ligands for human studies of activated microglia (TSPO over expression) was PKIII95, a lipid soluble isoquinoline carbox amide, and the their R-enantiomer labelled with carbon-II «( R)-[N-MethyPIC]PKllI95) [4] , and it still today the most widely used radiotracer for in vivo imaging of TSPO [5] .
Carbon-ll (He) is one of the most widely used radioiso topes in PET radiochemistry due to the ubiquity of the element in organic structures that allow it to be incorporated into bio molecules of interest without signifIcant loss of biological ac tivity, in contrast, for example, with the negative effect in the bioactivity of a promising compound after labelling with Fluo rine-I8 eSF). However, parallel reactions with the environmen tal [1 2 C]Carbon Dioxide ([1 2 C]COz) and a short half-life period (20,4 minutes) are some of the reasons that made the synthesis of high specifIc activity l1C radiotracers a real challenge. The development of automated radio synthesis modules using the captive solvent method has facilitated the production of radio tracers labelled with HC with rapid reactions and low amount of side products that can be quickly purifIed by semi-preparative HPLC and reformulated for preclinical and clinical use.
II.

GOALS
We report on the optimisation and automation of the syn thesis, purifIcation and reformulation of (R)-[N-Methyl-11C]PKI1l95 ([11C]PKI1l95) in order to produce a stable, sterile and ready-to-inject solution of the radiopharmaceutical with suffIcient activity and quality to be used for clinical in vivo PET imaging studies of neuroinflammation.
A substantial part of the work developed is applicable to other HC-labelled compounds and, in fact, has been of critical importance for the production of other tracers, notably 
III. EXPERIMENTAL
A. Materials and Apparatus
All irradiations were perfonned on IBA Cyclone 18/9 cy clotron (IBA, Louvain-Ia-neuve, Belgium) using high energy (18 MeV) protons.
Production of ["C]CH3I and conversion to ["C]CH30Tf was carried out using a methyl iodide production system (Bios can Inc., Washington DC, USA) and the methylations occurr ed in a specially designed loop (Auto loop system, Bioscan Inc., Washington DC, USA). The reaction products were purified using a semi preparative HPLC system composed by a HPLC K-501 pump (Knauer, Berlin, Germany), a Phenomenex Luna CI8(2) 5f.! (250xl0 mm) reverse phase HPLC column (Phe nomenex, Le Pecq Cedex, France), a UV K-200 detector set at 254 nm (Knauer, Berlin, Germany), and a suitable radiation detector. On the last step of the synthesis, the desired fraction was collected and formulated using a reformulation system (Bios can Inc., Washington DC, USA). Cold precursors ((R)-[N-Desmethyl]PKI1195 and others) were purchased from ABX (Advanced Biochemical Compounds, Radeberg, Genna ny) and all other reagents and solvents used in the syntheses were purchased from local suppliers are were of Phann. Eur. grade, when available.
Quality control (QC) of all radiotracers for PET synthesised during this work, in special ["C]PK1I195, were performed to verify their purity and safety for injection. For that purpose, an Agilent 1200 Series HPLC system (variable wavelength detec tor) with a Ray test Gabi Star 1207 radiometric detector (Ray testGmbh, Straubenhardt, Germany) and a Rheodyne (IDEX H&S, Wertheim-Mondfeld, Gennany) model 7125i syringe loading sample injector valve with a 20 f.!l loop was used. The chromatographic separation was performed using an analytical reverse phase Agilent Zorbax Eclipse XDB C18 column (150x4.5 mm; 5f.!). A dose calibrator (lSOMED 1010; Elimpex-Medizintechnik GesmbH, Modling, Austria) was used to measure the radioactivity concentration and the physical half-life of radioisotope. A gas chromatography (GC) system (GC Agilent 6850; RaytestGmbh, Straubenhardt, Gennany) was used to monitor residual solvents concentration in [mal product. The pH was measured using a pH meter (JENW A Y 3510 pH; Bibby Scientific Limited, Staffordshire, UK).
B.
Production oft'CjMethyllodide --1HF 
D. Purification of(R)-{N-Methyl-"CjPKll195
After the reaction on the loop is completed, the mixture is di rectly injected into a semi-preparative HPLC column for puri fication. The reverse phase column (CI8(2), 5f.!, 250x1O mm) is coupled to a ultra-violet detector at 254 nm and a radioactivi ty detector. The chosen eluent is O.lM ammonium formate aqueous solution/acetonitrile (40/60) at flow rate of 6 mUmin.
E.
Product Reformulation
After purification of labelled compounds by HPLC, they must be reformulated into ready-to-inject doses for clinical use. This is because the eluent of the HPLC is rarely compatible with injection to animals or humans. Reformulation is then needed to remove any organic solvent that may be present. For ["C]PKll195 the method used is solid phase extraction (SPE) [7] .
The product reformulation step is carried out on a reformula tion system using a sterile disposable kit optimised during this project and suitable reagents, following a sequence of steps which are determined by the user selected method. The method uses an SPE (CI8) cartridge to trap the ["C]PKl1I95 from the diluted HPLC mobile phase, rinses any residual organic sol vents, and releases the compound in a small volume of ethanol followed by dilution with NaCI 0.9% and filtration through a sterile 0.22 11m filter (Millex-GV, Millipore).
F.
Quality control
Chemical and radiochemical impurIties were detected and quantified using analytical radio-HPLC. Aqueous O.IM am monium formate/CH3CN (25/75; v/v) were used as mobile phase with a flow rate of 2 mllmin on a reverse phase C 18 (l50x4.5 mm; 511) analytical column. The whole HPLC analy sis was completed within 10 min, the retention time of the PKl1195 precursor was 2.5-3.l minutes and the product ["C]PKl1I95 was eluted with a retention time of 1.8-2.4 minutes.
IV. RESULTS
A process for full synthesis of (R)-[N-Methyl-"C]PKI1195 synthesis was optimised for routine in about 35 minutes from end of bombardment ( Figure 3 ). 
A. t' Cj Methyl Iodide Production
Production is completed in 1l.39±0.76 minutes (from EOB). The radiochemical yield and specific activity of [1lC]CH3I produced were 70.79±7.60% (non-decay corrected) and 18.47±2.69 GBq/llmol (499.32±72.77 mCi/Jlffi ol), respec tively.
a) Specific Activity Optimisations:
With the implementation of molecular sieves (MS) pre heating and inert gas filtering procedures (Table I) as well re ducing LiAlH4 volume, and load/unload target before each synthesis improving the specific activity of [1lC]CH3I as well as any compound labelled with this methylation agent. The contribution of bombarding time for the final amount of stable methyl iodide was also tested. As showed on Figure 4 , the major quantity of stable methyl iodide produced is on first IlAh of the bombarding time. These results enabled us to implement a procedure for rou tine production that can produce "C-labelled compounds with improved specific activities. 
Reformulation and sterile filtration of (R)-[N-Methyl IIClPKll195
SPE purification resulted in a recovery of>95 % using 1 ml of ethanol followed by 9 ml of physiological saline solution (NaCI 0.9%) for the elution of [1IC]PKll195.
Finally, the labelled compound «( R)-[N-Methyl-IIC]PKll195) was filtered through a sterile filter (Millex-GV 0.22 /lm) where the labelled product was quantitatively recov ered in the final vial without significantly retention of that on filter.
V.
DISCUSSION
The radioligand [11C]PKl195 was synthesised for the first time by the French company Pharmuka in 1984 [8] . The com pound is a non-benzodiazepine high-affinity selective TSPO ligand and was labelled with IIC as a PET imaging probe for neurointlammation. Despite the limitations of IIC, related to its short half-life, PKlll95 has remained the most widely used molecule for in vivo PET studies of TSPO.
The aim of this work was to optimise the synthesis, purifi cation and reformulation of [1IC]PKll195 by the captive sol vent method using a series of modules available at ICNAS (In stituto de Ciencias Nucleares Aplicadas a Saude) for the pro duction of methyl iodide, methylation in a captive solvent loop and reformulation by solid phase extraction. Automated radio synthesis of compounds is common in PET production centres as it diminishes considerably doses on staff, provides a reliable and reproducible platform for production and facilitates record keeping and GMP compliance. A fundamental step of the pro cess is the initial setup and optimisation of a synthesis that, considering there each installation is unique in its nature, re quires substantial work in adapting production methods from the literature to the specific setup of each site. Radiochemical purity exceeded 99% as determined by ra dio-HPLC. No contamination with [N-Desmethyl]PKllI95 precursor was observed ( Figure 6 ). Residual solvents as deter minate by GC were found to be 67.2 mg/ml ethanol and 0.3 mg/ml acetonitrile, and which is consistent with limits on European Pharmacopoeia (Ph. Eur.). pH was between 4.5-8.5. Specific activity of the final product was between 15-25 GBq//lffi ol. Syntheses yields were about lO-16 % (non-decay corrected). 1 -"
A. Routine Production
TIme (minutes) 
VI. CONCLUSIONS
PKll195 is a lipid soluble isoquinoline carboxamide that labelled with IIC, can be used as an in vivo molecular imaging probe for the TSPO receptor. This 18 kDa trans locator protein is overexpressed when microglia is activated, a main feature of neurointlammation.
Optimisation of the synthesis, purification and reformula tion of (R)-[N-Methyl-IIC]PKll195 using the captive solvent method were improved for routine production with excellent radiochemical yields and good specific activities, making it available on a ready to inject sterile saline solution for PET imaging studies of neurointlammation.
(R)-[N-Methyl IIC]PK11195 was obtained at end of synthesis with 5.54±1.86 GBq (l49.71±50.25 mCi) and specific activities between 15-25 GBq/ /lmol on a short overall synthesis time. All quality control tests were performed to ensure the good quality of product.
The approach that we have developed allows the reliable and reproducible preparation [IIC]-radiopharmaceuticals such as (R)-[IlC]PKlll95 several times a day, with activity and quality suitable for human studies. The optimisations made are applicable to most methylation syntheses by this method and are already being used at the lab for the development of the next generation of 'Ie-based radiotracers.
